One assignee leads the ranked field with 9 of the 30 records in scope, close to a third of the entire dataset by itself. The top 5 of 14 ranked assignees together account for 23 records, or 76.7% of all records in scope, meaning ownership is concentrated in a small group rather than spread evenly. Anyone evaluating freedom to operate should start by mapping that leading portfolio’s specific claims on needle configuration and energy delivery before assuming the space is open.

Filing activity peaked in 2021 at 9 records and had fallen to 2 by 2024, the last complete filing year, a 78% decline over that span. However, publication typically lags filing by roughly 18 months, so 2025 and 2026 figures in any dataset are still incomplete and should not be read as proof the field has stopped growing. A fair read is that the initial wave of core device claims has been filed, and any renewed growth would likely show up in classes not yet heavily claimed.

The dataset’s IPC composition shows diagnosis and surgery (A61B) as the largest category at 53.3% of the 30 records, followed by medicinal preparations (A61K) at 40.0% and electrotherapy/radiation therapy (A61N) at 33.3%. Sterilising and body-fluid device classes each cover 30.0% of records, while cosmetics-use classification (A61Q) covers only 3.3%. This distribution indicates that most defensible claims have historically centered on the delivery mechanism and safety controls rather than the cosmetic outcome itself.